Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
18.50
-0.05 (-0.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NovoCure Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Why NovoCure Stock Skyrocketed This Week
Today 13:21 EDT
Via
The Motley Fool
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Why NovoCure Stock Leaped 4% Higher Today
April 24, 2025
Via
The Motley Fool
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
April 24, 2025
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.
Via
Benzinga
Topics
World Trade
Exposures
Tariff
NovoCure Surpasses Q1 Expectations
April 24, 2025
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 24, 2025
Via
Benzinga
Earnings Scheduled For April 24, 2025
April 24, 2025
Via
Benzinga
NovoCure's Earnings: A Preview
April 23, 2025
Via
Benzinga
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
March 04, 2025
Via
The Motley Fool
Novocure Reports First Quarter 2025 Financial Results
April 24, 2025
From
Novocure
Via
Business Wire
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
April 23, 2025
From
Novocure
Via
Business Wire
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
April 22, 2025
From
Novocure
Via
Business Wire
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
January 14, 2025
Via
Benzinga
Why NovoCure Stock Was Winning Big This Week
December 06, 2024
Via
The Motley Fool
Why NovoCure Stock Was Withering on Wednesday
April 16, 2025
Via
The Motley Fool
Novocure to Report First Quarter 2025 Financial Results
April 01, 2025
From
Novocure
Via
Business Wire
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
March 04, 2025
From
Novocure
Via
Business Wire
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
February 27, 2025
NVCR earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
February 27, 2025
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion.
Via
Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
February 27, 2025
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
Via
The Motley Fool
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
February 27, 2025
From
Novocure
Via
Business Wire
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
January 30, 2025
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
Via
Benzinga
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
January 13, 2025
From
Novocure
Via
Business Wire
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
January 03, 2025
From
Novocure
Via
Business Wire
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
December 15, 2024
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.
Via
Benzinga
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
December 08, 2024
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks.
Via
Benzinga
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
December 05, 2024
Via
The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 02, 2024
Via
Benzinga
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
December 02, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
December 02, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.